BR9909109A - Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela - Google Patents

Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela

Info

Publication number
BR9909109A
BR9909109A BR9909109-7A BR9909109A BR9909109A BR 9909109 A BR9909109 A BR 9909109A BR 9909109 A BR9909109 A BR 9909109A BR 9909109 A BR9909109 A BR 9909109A
Authority
BR
Brazil
Prior art keywords
yucca
function
deficiency
membrane
smilagenin
Prior art date
Application number
BR9909109-7A
Other languages
English (en)
Inventor
Zongqin Xia
Yaer Hu
Ian Rubin
Jonathan Brostoff
Brian Whittle
Weijun Wang
Phil Gunning
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806513.9A external-priority patent/GB9806513D0/en
Priority claimed from GBGB9905275.5A external-priority patent/GB9905275D0/en
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of BR9909109A publication Critical patent/BR9909109A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine

Abstract

"USOS DE UM OU MAIS DENTRE ESMILAGENINA, PRAZERIGENINA, UM ASTRAGALOSìDEO, TIGOGENINA, RUSCOGENINA, HECOGENINA, DE DIOSGENINA, DE ESMILAGENINA, ANZUROGENINA D OU UM ASTRAGALOSìDEO E DE UM EXTRATO DE UMA PLANTA DO GêNERO SMILAX, ASPARAGUS, ANEMARRHENA, YUCCA OU AGAVE, COMPOSIçãO PARA O TRATAMENTO DE UMA CONDIçãO DISTINGUIDA POR UMA DEFICIêNCIA DA FUNçãO OU DO NúMERO DE RECEPTORES PóS-SINáPTICOS LIGADOS A MEMBRANA, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA ACENTUAR A FUNçãO COGNITIVA EM UM HUMANO OU ANIMAL NãO-HUMANO E EM UM PACIENTE QUE SOFRE DE UMA DISFUNçãO COGNITIVA RELACIONADA COM A IDADE, E PARA TRATAR UMA CONDIçãO DISTRINGUIDA POR UMA DEFICIêNCIA DA FUNçãO OU DO NúMERO DE RECEPTORES LIGADOS A MEMBRANA EM UM TECIDO, óRGãO, TIPO DE CéLULA OU ORGANELA". A invenção descreve o uso de uma quantidade de saponinas e sapogeninas, principalmente aquelas com estrutura esteróide, no tratamento da disfunção cognitiva e de condições semelhantes. Também se descreve processos de tratamento e composições farmacêuticas.
BR9909109-7A 1998-03-26 1999-03-26 Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela BR9909109A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806513.9A GB9806513D0 (en) 1998-03-26 1998-03-26 Membrane-bound receptors
GBGB9905275.5A GB9905275D0 (en) 1999-03-08 1999-03-08 Treatment of conditions associated with membrane-bound receptors and their function
PCT/GB1999/000951 WO1999048507A2 (en) 1998-03-26 1999-03-26 Steroidal saponins for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
BR9909109A true BR9909109A (pt) 2000-12-12

Family

ID=26313369

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9909110-0A BR9909110A (pt) 1998-03-26 1999-03-26 Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR9909109-7A BR9909109A (pt) 1998-03-26 1999-03-26 Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9909110-0A BR9909110A (pt) 1998-03-26 1999-03-26 Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo

Country Status (28)

Country Link
US (2) US6812213B2 (pt)
EP (3) EP1719512B1 (pt)
JP (4) JP2003524581A (pt)
KR (6) KR20090009997A (pt)
CN (3) CN1198622C (pt)
AT (3) ATE337788T1 (pt)
AU (2) AU3158199A (pt)
BR (2) BR9909110A (pt)
CA (2) CA2325634A1 (pt)
CY (1) CY1105653T1 (pt)
DE (3) DE69929177T2 (pt)
DK (2) DK1066042T3 (pt)
ES (2) ES2272060T3 (pt)
GB (1) GB2335599B (pt)
HK (3) HK1033742A1 (pt)
HR (2) HRP20000637A2 (pt)
HU (2) HUP0103654A2 (pt)
ID (2) ID26781A (pt)
IL (4) IL138663A0 (pt)
IS (2) IS5638A (pt)
MX (1) MXPA00009437A (pt)
NO (4) NO20004804L (pt)
NZ (1) NZ507355A (pt)
PL (3) PL343508A1 (pt)
PT (1) PT1066042E (pt)
RU (1) RU2297228C2 (pt)
TR (2) TR200002773T2 (pt)
WO (2) WO1999048507A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277978B1 (en) 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
KR20090009997A (ko) * 1998-03-26 2009-01-23 파이토팜 피엘씨 알츠하이머병을 치료하기 위한 스밀라게닌 및 안주로게닌-ｄ
US20030118673A1 (en) * 1998-03-26 2003-06-26 Zongqin Xia Smilagenin and anzurogenin-D for the treatment of alzheimer's disease
AU781810B2 (en) * 1998-03-26 2005-06-16 Phytopharm Plc. Steroidal sapogenins and their derivatives for treating Alzheimer's disease
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
NZ563183A (en) * 2002-03-27 2009-03-31 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
IL164161A0 (en) * 2002-03-27 2005-12-18 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
JP4573157B2 (ja) * 2002-03-27 2010-11-04 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
PL210114B1 (pl) 2002-10-28 2011-12-30 Phytopharm Plc Sposób stereospecyficznego wytwarzania 3β-hydroksy-5β-H-steroidowych sapogenin
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0409567D0 (en) * 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
CA2584333A1 (en) * 2004-10-14 2006-04-27 Georgetown University Neuroprotective spirostenol pharmaceutical compositions
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR100779179B1 (ko) * 2006-05-19 2007-11-28 충북대학교 산학협력단 토복령의 메탄올 추출물을 함유하는 뇌신경 보호 또는퇴행성뇌질환 예방 또는 치료제
JP2009256243A (ja) * 2008-04-17 2009-11-05 Noevir Co Ltd 保湿剤、抗老化剤、抗酸化剤、皮膚外用剤及び機能性経口組成物
US8217165B2 (en) 2008-06-17 2012-07-10 Pawan Kumar Goel Process for the extraction of furostanolic saponins from fenugreek seeds
KR101027384B1 (ko) * 2009-06-29 2011-04-11 에이디엠이십일 주식회사 플랫와이퍼블레이드와 와이퍼아암의 연결장치
WO2010084356A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
TWI422378B (zh) * 2010-11-18 2014-01-11 Univ Chung Shan Medical 使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷
CN102389438A (zh) * 2011-06-30 2012-03-28 北京师范大学 黄芪甲苷的应用
WO2014112145A1 (ja) * 2013-01-21 2014-07-24 レジリオ株式会社 アルツハイマー病等を含む神経疾患の1,25d3-marrsが関与する治療薬及び治療法
KR101777920B1 (ko) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물
CN105168785A (zh) * 2015-10-08 2015-12-23 湖北民族学院 一种治疗阿尔茨海默病的中药制剂及制备方法
EP3572085A1 (en) * 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN108514603B (zh) * 2018-06-28 2021-12-28 佳木斯大学 一种治疗强直型帕金森病的中药组合物及其制备方法
KR102028730B1 (ko) 2019-05-22 2019-10-04 (주)클래시스 집속초음파 기술을 이용한 지모 추출물의 제조방법 및 이로부터 수득된 지모 추출물
CN110859849A (zh) * 2019-12-11 2020-03-06 大连医科大学 薯蓣皂苷在制备帕金森病保护药物中的应用
US11788574B2 (en) 2021-08-13 2023-10-17 Rimgard Sweden AB Anti-theft locking bolt assembly

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
DE69131861T2 (de) * 1990-01-18 2000-05-18 Cura Nominees Pty Ltd Glykoalkaloide
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
SK158394A3 (en) * 1992-06-26 1995-05-10 Pfizer Steroidal glycosides
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
CN1092992A (zh) * 1993-03-29 1994-10-05 中国科学院沈阳应用生态研究所 提高脑功能的药物及其制备方法
CN1052636C (zh) * 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 文冠果子的醇提取物在制备治疗智力低下的药物中的应用
CZ280195A3 (en) * 1993-04-28 1996-02-14 Pfizer Crystalline spirostanyl glycoside, monohydrate thereof, pharmaceutical composition based thereon and process for preparing crystalline steroidal glycoside
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0737202A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemic agents
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
AU2265395A (en) * 1994-08-30 1996-03-22 Pfizer Inc. Spirostanyl glycosidal crystals
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
CA2301860C (en) * 1997-08-28 2009-05-26 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
KR20090009997A (ko) * 1998-03-26 2009-01-23 파이토팜 피엘씨 알츠하이머병을 치료하기 위한 스밀라게닌 및 안주로게닌-ｄ
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol

Also Published As

Publication number Publication date
IL138664A0 (en) 2001-10-31
AU3158199A (en) 1999-10-18
NO20004804D0 (no) 2000-09-26
KR20070117001A (ko) 2007-12-11
PL343508A1 (en) 2001-08-27
US20060182817A1 (en) 2006-08-17
NO20085251L (no) 2000-11-09
CN1198622C (zh) 2005-04-27
GB2335599A (en) 1999-09-29
HRP20000638A2 (en) 2001-04-30
KR20010042205A (ko) 2001-05-25
TR200002773T2 (tr) 2001-11-21
PL380866A1 (pl) 2001-08-13
PT1066042E (pt) 2006-12-29
CN1679591A (zh) 2005-10-12
CY1105653T1 (el) 2010-12-22
PL343423A1 (en) 2001-08-13
NO20083993L (no) 2000-09-11
ATE314057T1 (de) 2006-01-15
DE69929177T2 (de) 2006-08-24
NO20004804L (no) 2000-11-09
JP2002507572A (ja) 2002-03-12
JP2003524581A (ja) 2003-08-19
RU2004123463A (ru) 2006-01-27
HK1091417A1 (en) 2007-01-19
HK1033903A1 (en) 2001-10-05
EP1066033B1 (en) 2005-12-28
JP3768100B2 (ja) 2006-04-19
PL207723B1 (pl) 2011-01-31
KR101092050B1 (ko) 2011-12-12
KR20070007214A (ko) 2007-01-12
EP1066042B1 (en) 2006-08-30
WO1999048482A2 (en) 1999-09-30
GB2335599B (en) 2001-08-01
KR20090007505A (ko) 2009-01-16
PL195897B1 (pl) 2007-11-30
ES2257042T3 (es) 2006-07-16
DE69943415D1 (de) 2011-06-16
EP1719512A3 (en) 2007-04-11
KR100632052B1 (ko) 2006-10-04
WO1999048507A2 (en) 1999-09-30
DK1066042T3 (da) 2006-12-18
KR100713311B1 (ko) 2007-05-04
KR20090009997A (ko) 2009-01-23
EP1719512A2 (en) 2006-11-08
IL174991A0 (en) 2006-08-20
HRP20000637A2 (en) 2001-04-30
TR200002774T2 (tr) 2001-06-21
ID26989A (id) 2001-02-22
IS5638A (is) 2000-09-25
AU748138B2 (en) 2002-05-30
CA2325633A1 (en) 1999-09-30
IS5637A (is) 2000-09-25
HK1033742A1 (en) 2001-09-21
AU3157499A (en) 1999-10-18
DE69929177D1 (de) 2006-02-02
CN1302208A (zh) 2001-07-04
WO1999048507A3 (en) 1999-11-25
CA2325633C (en) 2009-01-20
NO20004803D0 (no) 2000-09-26
RU2297228C2 (ru) 2007-04-20
DE69933016T2 (de) 2007-03-29
JP2004217666A (ja) 2004-08-05
IL138663A0 (en) 2001-10-31
KR20010042190A (ko) 2001-05-25
ATE337788T1 (de) 2006-09-15
HUP0101693A3 (en) 2002-08-28
CN1209112C (zh) 2005-07-06
GB9907100D0 (en) 1999-05-19
NZ507355A (en) 2004-02-27
IL138663A (en) 2006-08-01
JP2004224797A (ja) 2004-08-12
ES2272060T3 (es) 2007-04-16
HUP0103654A2 (hu) 2002-02-28
HUP0101693A2 (hu) 2001-12-28
EP1066033A1 (en) 2001-01-10
EP1066042A2 (en) 2001-01-10
US20020193317A1 (en) 2002-12-19
EP1719512B1 (en) 2011-05-04
MXPA00009437A (es) 2002-05-06
NO20004803L (no) 2000-11-27
ATE507834T1 (de) 2011-05-15
CN1301166A (zh) 2001-06-27
CN100377714C (zh) 2008-04-02
ID26781A (id) 2001-02-08
BR9909110A (pt) 2000-12-12
WO1999048482A3 (en) 2000-11-23
US6812213B2 (en) 2004-11-02
CA2325634A1 (en) 1999-09-30
DK1719512T3 (da) 2011-08-15
DE69933016D1 (de) 2006-10-12

Similar Documents

Publication Publication Date Title
BR9909109A (pt) Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela
Seetharam et al. Hypoglycemic activity of Abutilon indicum leaf extracts in rats
Allard et al. Characterization and localization of a putative morphine-modulating peptide, FLFQPQRFamide, in the rat spinal cord: biochemical and immunocytochemical studies
Martinez et al. Abnormal secretory response to parasympathomimetic and sympathomimetic stimulations from the submaxillary gland of rats treated with reserpine.
Gemmell et al. Ultrastructural and biochemical evidence for a steroid-containing secretory organelle in the perfused cat adrenal gland.
Papp Different effects of short-and long-term treatment with imipramine on the apomorphine-and food-induced place preference conditioning in rats
Suzuki et al. The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice
de Lores Arnaiz et al. Characterization of synaptosomal membrane Na+, K+-ATPase inhibitors
Ferrary et al. Hormonal modulation of inner ear fluids
Kovalchuk et al. Estrogenic activity of triterpene glycosides in yeast two-hybrid assay
Brun et al. Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens
Kaur et al. A review on leucoderma and reported herbs for its treatment
Stein et al. Central serotonergic influences on renal electrolyte and water excretion
Thombs et al. Weight-loss expectancies, relative weight, and symptoms of bulimia in young women.
CA2344633A1 (en) Methods for determining the activity of complex mixtures
Babu et al. Studies on anatomy and phytochemical analysis of Ipomoea pes-tigridis L.
Dupont et al. DISTRIBUTION OF RADIOACTIVITY IN THE ORGANS OF THE RAT AND MOUSE AFTER INJECTION OF l-[3H] PROLYL-l-LEUCYL-GLYCINAMIDE
Begum et al. In vivo evaluation of antidiarrhoeal activity of the leaves of Azima tetracantha Linn
Hoffmann et al. Aldosterone regulates paracellular pathway resistance in rabbit distal colon
Mazzanti et al. Conferring drug resistance by MDR1 gene transfection increases susceptibility to irradiation and lipid peroxidation in 3T3 cell line
Basha et al. In-vitro anthelmintic efficacy of the 80% hydro-alcohol extract of Myrsine africana (kechemo) leaf on hookworm larvae
Finkelstein et al. Immobilization stress and direct glucocorticoid effects on rat septohippocampus
Nagaraju et al. In-vitro studies on anti-diabetic and wound healing activity of Chloroxylon swietenia Linn (Rutaceae) leaf extract
Sakaguchi et al. Changes in food intake after hepatic vagotomy at a stage of development in rats
Kadry et al. Diuretic activity of alcoholic extract of Tribulus alatus in rats

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 37 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]